<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011592</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-0416</org_study_id>
    <nct_id>NCT04011592</nct_id>
  </id_info>
  <brief_title>Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression</brief_title>
  <official_title>Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum depression is a non-psychotic major or minor depressive episode that occurs during&#xD;
      pregnancy or within 12 months of post-partum period. The nature of symptoms is same as&#xD;
      depressive episode characterized by depressed mood, anxiety, sleep difficulties, suicidal&#xD;
      thoughts, tiredness and diminished interest in pleasurable activities. Severe maternal&#xD;
      depression affects children by increasing the risk of emotional and behavioral and physical&#xD;
      health problems and cognitive difficulties. Thus early screening and intervention is critical&#xD;
      in reducing the negative impact of PND in the mother and child, family and the community.&#xD;
&#xD;
      The purpose of this study is to assess the safety, pharmacokinetics and antidepressant&#xD;
      efficacy of sub-anesthetic dose of intravenous ketamine in perinatal depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment not feasible&#xD;
  </why_stopped>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Actual">September 9, 2019</completion_date>
  <primary_completion_date type="Actual">September 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Depressed Mood as Indicated by Hamilton Depression Rating Scale (HAM-D) Score</measure>
    <time_frame>baseline, 24 hours post-injection</time_frame>
    <description>The Hamilton Depression Rating Scale (HAM-D) score ranges from 0-53. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates at least moderate severity of depressive symptoms. The value reported is the score at baseline minus the score 24 hours post-injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-Emergent Adverse Events</measure>
    <time_frame>24 hours post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Postnatal Depression as Indicated by Edinburgh Postnatal Depression Scale (EPDS) Scale</measure>
    <time_frame>baseline, 24 hours post-injection</time_frame>
    <description>The Edinburgh Postnatal Depression Scale (EPDS) score ranges from 0 to 30. Higher scores indicate worse outcome, with a score of 10 or greater indicating depression. The value reported is the score at baseline minus the score at 24 hours post-injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anxiety as Indicated by Generalized Anxiety Disorder 7-Item (GAD-7) Scale</measure>
    <time_frame>baseline, 24 hours post-injection</time_frame>
    <description>The Generalized Anxiety Disorder 7-Item (GAD-7) Scale score ranges from 0 to 21, with higher scores indicating greater anxiety. The value reported is the score at baseline minus the score 24 hours post-injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depression as Indicated by Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>baseline, 24 hours post-injection</time_frame>
    <description>The Patient Health Questionnaire (PHQ-9) score ranges from 0 to 27, with greater scores indicating more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Behavioral Suicidal Events (Suicidal Ideation), as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>baseline, 24 hours post-injection</time_frame>
    <description>The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. The first part (Items 1-5) rates an individual's degree of suicidal ideation on a 0-5 scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent and behaviors&quot;. The C-SSRS outcomes are categories and have binary responses (yes/no). Suicidal ideation is considered when the patient responds a &quot;yes&quot; answer at any time during treatment to any one of the five suicidal ideation questions (Categories 1-5) on the C-SSRS. The sum of the 5 intensity item scores create a total score (range 0 to 25) to represent the intensity rating (higher scores indicate more severe suicidal ideation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Behavioral Suicidal Events (Suicidal Behavior), as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>baseline, 24 hours post-injection</time_frame>
    <description>The questions 6-10 of the C-SSRS are related to suicidal behavior, and the outcome is a simple yes/no response. Suicidal behavior occurs if the patient answers a &quot;yes&quot; at any time during treatment to any one of the five suicidal behavior questions (Categories 6-10) on the C-SSRS.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Post Partum Depression</condition>
  <arm_group>
    <arm_group_label>Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.5 mg/kg</intervention_name>
    <description>single intravenous infusion of Ketamine (0.5 mg/kg)</description>
    <arm_group_label>Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg</arm_group_label>
    <arm_group_label>Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg</arm_group_label>
    <other_name>Ketamine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 0.2 mg/kg</intervention_name>
    <description>single intravenous infusion of Ketamine (0.2 mg/kg)</description>
    <arm_group_label>Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg</arm_group_label>
    <arm_group_label>Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subjects, ages 18-45 years&#xD;
&#xD;
          -  Experienced a major depressive episode in the postpartum period beginning within the&#xD;
             first 4 weeks following delivery and with moderate or severe symptoms (&gt;12 EPDS or &gt;14&#xD;
             HAM-D).&#xD;
&#xD;
          -  No or partial response to adequate doses of SSRI medications to treat PND for longer&#xD;
             than 6 weeks.&#xD;
&#xD;
          -  PND patients will be requested to maintain the stable dose of antidepressants while&#xD;
             enrolled in the study trial.&#xD;
&#xD;
          -  Patients that can speak and read the English language, are able to understand the&#xD;
             study procedures and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No current or past psychosis or severe personality disorder.&#xD;
&#xD;
          -  No current substance abuse or dependence.&#xD;
&#xD;
          -  No serious and imminent suicidal or homicidal risk.&#xD;
&#xD;
          -  No recent or history of major and unstable medical problems that affect brain anatomy,&#xD;
             neurochemistry, or function.&#xD;
&#xD;
          -  Not diagnosed with cardiovascular disorders.&#xD;
&#xD;
          -  No increased risk of laryngospasm or active upper respiratory infections.&#xD;
&#xD;
          -  Not diagnosed with an intellectual disability or neurodegenerative diseases.&#xD;
&#xD;
          -  Mothers that are currently breastfeeding.&#xD;
&#xD;
          -  No current pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudhakar Selvaraj, 713-486-2837</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHealth Science Center at Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <results_first_submitted>August 24, 2020</results_first_submitted>
  <results_first_submitted_qc>August 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2020</results_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Sudhakar Selvaraj</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04011592/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine 0.5 mg/kg, Then Ketamine 0.2 mg/kg</title>
          <description>single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)&#xD;
Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)&#xD;
Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
        </group>
        <group group_id="P2">
          <title>Ketamine 0.2 mg/kg, Then Ketamine 0.5 mg/kg</title>
          <description>single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)&#xD;
Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)&#xD;
Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only one participant was enrolled, and this participant received 0.5 mg/kg Ketamine, then 0.2 mg/kg Ketamine.</population>
      <group_list>
        <group group_id="B1">
          <title>Ketamine 0.5 mg/kg, Then Ketamine 0.2 mg/kg</title>
          <description>single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)&#xD;
Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)&#xD;
Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
        </group>
        <group group_id="B2">
          <title>Ketamine 0.2 mg/kg, Then Ketamine 0.5 mg/kg</title>
          <description>single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)&#xD;
Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)&#xD;
Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="NA">Standard Deviation is not calculable for 1 participant.</measurement>
                    <measurement group_id="B3" value="37" spread="NA">Standard Deviation is not calculable for 1 participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Depressed Mood as Indicated by Hamilton Depression Rating Scale (HAM-D) Score</title>
        <description>The Hamilton Depression Rating Scale (HAM-D) score ranges from 0-53. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates at least moderate severity of depressive symptoms. The value reported is the score at baseline minus the score 24 hours post-injection.</description>
        <time_frame>baseline, 24 hours post-injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.5 mg/kg</title>
            <description>Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2 mg/kg</title>
            <description>Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depressed Mood as Indicated by Hamilton Depression Rating Scale (HAM-D) Score</title>
          <description>The Hamilton Depression Rating Scale (HAM-D) score ranges from 0-53. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates at least moderate severity of depressive symptoms. The value reported is the score at baseline minus the score 24 hours post-injection.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="NA">Standard Deviation is not calculable for 1 participant.</measurement>
                    <measurement group_id="O2" value="3" spread="NA">Standard Deviation is not calculable for 1 participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treatment-Emergent Adverse Events</title>
        <time_frame>24 hours post-injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.5 mg/kg</title>
            <description>Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2 mg/kg</title>
            <description>Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-Emergent Adverse Events</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mild headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Postnatal Depression as Indicated by Edinburgh Postnatal Depression Scale (EPDS) Scale</title>
        <description>The Edinburgh Postnatal Depression Scale (EPDS) score ranges from 0 to 30. Higher scores indicate worse outcome, with a score of 10 or greater indicating depression. The value reported is the score at baseline minus the score at 24 hours post-injection.</description>
        <time_frame>baseline, 24 hours post-injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.5 mg/kg</title>
            <description>Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2 mg/kg</title>
            <description>Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Postnatal Depression as Indicated by Edinburgh Postnatal Depression Scale (EPDS) Scale</title>
          <description>The Edinburgh Postnatal Depression Scale (EPDS) score ranges from 0 to 30. Higher scores indicate worse outcome, with a score of 10 or greater indicating depression. The value reported is the score at baseline minus the score at 24 hours post-injection.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="NA">Standard Deviation is not calculable for 1 participant.</measurement>
                    <measurement group_id="O2" value="2" spread="NA">Standard Deviation is not calculable for 1 participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Anxiety as Indicated by Generalized Anxiety Disorder 7-Item (GAD-7) Scale</title>
        <description>The Generalized Anxiety Disorder 7-Item (GAD-7) Scale score ranges from 0 to 21, with higher scores indicating greater anxiety. The value reported is the score at baseline minus the score 24 hours post-injection.</description>
        <time_frame>baseline, 24 hours post-injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.5 mg/kg</title>
            <description>Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2 mg/kg</title>
            <description>Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Anxiety as Indicated by Generalized Anxiety Disorder 7-Item (GAD-7) Scale</title>
          <description>The Generalized Anxiety Disorder 7-Item (GAD-7) Scale score ranges from 0 to 21, with higher scores indicating greater anxiety. The value reported is the score at baseline minus the score 24 hours post-injection.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="NA">Standard Deviation is not calculable for 1 participant.</measurement>
                    <measurement group_id="O2" value="0" spread="NA">Standard Deviation is not calculable for 1 participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depression as Indicated by Patient Health Questionnaire (PHQ-9)</title>
        <description>The Patient Health Questionnaire (PHQ-9) score ranges from 0 to 27, with greater scores indicating more severe depression.</description>
        <time_frame>baseline, 24 hours post-injection</time_frame>
        <population>This outcome measure was not assessed and no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.5 mg/kg</title>
            <description>Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2 mg/kg</title>
            <description>Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depression as Indicated by Patient Health Questionnaire (PHQ-9)</title>
          <description>The Patient Health Questionnaire (PHQ-9) score ranges from 0 to 27, with greater scores indicating more severe depression.</description>
          <population>This outcome measure was not assessed and no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Behavioral Suicidal Events (Suicidal Ideation), as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)</title>
        <description>The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. The first part (Items 1-5) rates an individual's degree of suicidal ideation on a 0-5 scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent and behaviors&quot;. The C-SSRS outcomes are categories and have binary responses (yes/no). Suicidal ideation is considered when the patient responds a &quot;yes&quot; answer at any time during treatment to any one of the five suicidal ideation questions (Categories 1-5) on the C-SSRS. The sum of the 5 intensity item scores create a total score (range 0 to 25) to represent the intensity rating (higher scores indicate more severe suicidal ideation).</description>
        <time_frame>baseline, 24 hours post-injection</time_frame>
        <population>This outcome measure was not assessed and no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.5 mg/kg</title>
            <description>Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2 mg/kg</title>
            <description>Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Behavioral Suicidal Events (Suicidal Ideation), as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)</title>
          <description>The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. The first part (Items 1-5) rates an individual's degree of suicidal ideation on a 0-5 scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent and behaviors&quot;. The C-SSRS outcomes are categories and have binary responses (yes/no). Suicidal ideation is considered when the patient responds a &quot;yes&quot; answer at any time during treatment to any one of the five suicidal ideation questions (Categories 1-5) on the C-SSRS. The sum of the 5 intensity item scores create a total score (range 0 to 25) to represent the intensity rating (higher scores indicate more severe suicidal ideation).</description>
          <population>This outcome measure was not assessed and no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Behavioral Suicidal Events (Suicidal Behavior), as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)</title>
        <description>The questions 6-10 of the C-SSRS are related to suicidal behavior, and the outcome is a simple yes/no response. Suicidal behavior occurs if the patient answers a &quot;yes&quot; at any time during treatment to any one of the five suicidal behavior questions (Categories 6-10) on the C-SSRS.</description>
        <time_frame>baseline, 24 hours post-injection</time_frame>
        <population>This outcome measure was not assessed and no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine 0.5 mg/kg</title>
            <description>Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>Ketamine 0.2 mg/kg</title>
            <description>Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Behavioral Suicidal Events (Suicidal Behavior), as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)</title>
          <description>The questions 6-10 of the C-SSRS are related to suicidal behavior, and the outcome is a simple yes/no response. Suicidal behavior occurs if the patient answers a &quot;yes&quot; at any time during treatment to any one of the five suicidal behavior questions (Categories 6-10) on the C-SSRS.</description>
          <population>This outcome measure was not assessed and no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketamine 0.5 mg/kg</title>
          <description>Ketamine 0.5 mg/kg: single intravenous infusion of Ketamine (0.5 mg/kg)</description>
        </group>
        <group group_id="E2">
          <title>Ketamine 0.2 mg/kg</title>
          <description>Ketamine 0.2 mg/kg: single intravenous infusion of Ketamine (0.2 mg/kg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mild headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Moderate Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only one subject was enrolled, and enrollment goal not met.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sudhakar Selvaraj, MD, PhD, Assistant Professor</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>713-486-2837</phone>
      <email>Sudhakar.Selvaraj@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

